Warning: The NCBI web site requires JavaScript to function. more...
The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study.
Wolfe F, Michaud K.
Arthritis Res Ther. 2010;12(2):R35. Epub 2010 Mar 2.
Related citations
The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis.
Symmons D, Tricker K, Roberts C, Davies L, Dawes P, Scott DL.
Health Technol Assess. 2005 Sep;9(34):iii-iv, ix-x, 1-78.
[Impact of disease progression on health status, quality of life and costs in rheumatoid arthritis in Hungary].
Péntek M, Szekanecz Z, Czirják L, Poór G, Rojkovich B, Polgár A, Genti G, Kiss CG, Sándor Z, Májer I, Brodszky V, Gulácsi L.
Orv Hetil. 2008 Apr 20;149(16):733-41. Hungarian.
Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.
Michaud K, Messer J, Choi HK, Wolfe F.
Arthritis Rheum. 2003 Oct;48(10):2750-62.
Changes in Health Assessment Questionnaire disability scores over five years in patients with rheumatoid arthritis compared with the general population.
Sokka T, Kautiainen H, Hannonen P, Pincus T.
Arthritis Rheum. 2006 Oct;54(10):3113-8.
Use of the Stanford Health Assessment Questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritis.
Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Hakala M, Luukkainen R, Vuori K, Blåfield H, Leirisalo-Repo M.
Scand J Rheumatol. 2009 Mar-Apr;38(2):96-103.
Scale characteristics and mapping accuracy of the US EQ-5D, UK EQ-5D, and SF-6D in patients with rheumatoid arthritis.
Wolfe F, Michaud K, Wallenstein G.
J Rheumatol. 2010 Aug 1;37(8):1615-25. Epub 2010 Jun 15. Erratum in: J Rheumatol. 2010 Sep;37(9):1979.
Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, Symmons D.
Rheumatology (Oxford). 2007 Aug;46(8):1345-54. Epub 2007 Jun 11.
What factors influence the health status of patients with rheumatoid arthritis measured by the SF-12v2 Health Survey and the Health Assessment Questionnaire?
Linde L, Sørensen J, Østergaard M, Hørslev-Petersen K, Rasmussen C, Jensen DV, Hetland ML.
J Rheumatol. 2009 Oct;36(10):2183-9. Epub 2009 Sep 1.
Radiographic damage in rheumatoid arthritis correlates with functional disability but not direct medical costs.
Clarke AE, St-Pierre Y, Joseph L, Penrod J, Sibley JT, Haga M, Genant HK.
J Rheumatol. 2001 Nov;28(11):2416-24.
Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Finckh A, Bansback N, Marra CA, Anis AH, Michaud K, Lubin S, White M, Sizto S, Liang MH.
Ann Intern Med. 2009 Nov 3;151(9):612-21.
Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.
Vera-Llonch M, Massarotti E, Wolfe F, Shadick N, Westhovens R, Sofrygin O, Maclean R, Li T, Oster G.
J Rheumatol. 2008 Sep;35(9):1745-53. Epub 2008 Jul 15.
UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug.
Kielhorn A, Porter D, Diamantopoulos A, Lewis G.
Curr Med Res Opin. 2008 Sep;24(9):2639-50. Epub 2008 Aug 6.
[A multicenter cross-sectional study on the health related quality of life of patients with rheumatoid arthritis using a revised Japanese version of the arthritis impact measurement scales version 2 (AIMS 2), focusing on the medical care costs and their associative factors].
Hashimoto A, Sato H, Nishibayahi Y, Shiino Y, Kutsuna T, Ishihara Y, Hoshi K, Fujimori J, Tsuboi S, Kondo H, Akizuki M, Moroi Y, Yoshida S.
Ryumachi. 2002 Feb;42(1):23-39. Japanese.
Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis.
Tanno M, Nakamura I, Ito K, Tanaka H, Ohta H, Kobayashi M, Tachihara A, Nagashima M, Yoshino S, Nakajima A.
Mod Rheumatol. 2006;16(2):77-84.
Measuring functional disability in early rheumatoid arthritis: the validity, reliability and responsiveness of the Recent-Onset Arthritis Disability (ROAD) index.
Salaffi F, Stancati A, Neri R, Grassi W, Bombardieri S.
Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S31-42.
Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol.
Ariza-Ariza R, Hernández-Cruz B, Carmona L, Dolores Ruiz-Montesinos M, Ballina J, Navarro-Sarabia F; Costs and Quality of Life in Rheumatoid Arthritis Study Group.
Arthritis Rheum. 2006 Oct 15;55(5):751-6.
Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.
Vera-Llonch M, Massarotti E, Wolfe F, Shadick N, Westhovens R, Sofrygin O, Maclean R, Yuan Y, Oster G.
Rheumatology (Oxford). 2008 Apr;47(4):535-41.
Long-term followup of health status in patients with severe rheumatoid arthritis after high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation.
Teng YK, Verburg RJ, Sont JK, van den Hout WB, Breedveld FC, van Laar JM.
Arthritis Rheum. 2005 Aug;52(8):2272-6.
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.
Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on